Dr. Christian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Fl 5
Columbus, OH 43210Phone+1 614-293-8619Fax+1 614-293-6420
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2006 - 2009- Ohio State University HospitalResidency, Internal Medicine, 2002 - 2005
- Ohio State University College of MedicineClass of 2002
Certifications & Licensure
OH State Medical License 2002 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2009 Sep 01
- A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2011 Oct 13
- Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2012 Feb 09
- Join now to see all
Publications & Presentations
PubMed
- Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.Paolo Strati, Rebecca Champion, Morton Coleman, Sonali M Smith, Parameswaran Venugopal
British Journal of Haematology. 2024-12-01 - Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.Narendranath Epperla, Ying Huang, Amanda F Cashen, John L Vaughn, Walter Hanel
Blood Advances. 2024-11-12 - 1 citationsEvaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study.Natalie S Grover, Kaitlin Annunzio, Marcus Watkins, Pallawi Torka, Reem Karmali
Blood Cancer Journal. 2024-10-18
Abstracts/Posters
- Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...Beth A. Christian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell LymphomaBeth A. Christian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 StudyBeth A. Christian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 StudiesClinically Re...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
